Particle size reduction for improvement of oral absorption of the poorly soluble drug UG558 in rats during early development

Drug Development and Industrial Pharmacy

Volumn 35, Issue 12, 2009, Pages 1479-1486

  Sigfridsson, Kalle ^a   Lundqvist, Anders J ^a   Strimfors, Marie ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Dissolution rate; Nanosuspension; Pharmacokinetic; Poorly soluble; Suspension

Indexed keywords

DRUG; UG 558; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG SOLUBILITY; FEMALE; LASER DIFFRACTION; NANOCHEMISTRY; NONHUMAN; PARTICLE SIZE; RAT; TOXICITY TESTING;

ADMINISTRATION, ORAL; ANIMALS; CARDIOVASCULAR AGENTS; FEMALE; HALF-LIFE; INTESTINAL ABSORPTION; NANOPARTICLES; PARTICLE SIZE; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; SUSPENSIONS;

EID: 71049183092     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639040903025855     Document Type: Article

References (32)

1. Lipinski CJ. (2001). Avoiding investment in doomed drugs. Is poor solubility an industry wide problem? Curr Drug Dis, 4:17-19.
2. Lipinski CJ. (2002). Poor aqueous solubility-an industry wide problem in drug discovery. Am Pharm Rev, 5:82-85
3. Loftsson T, Brewster ME. (1996). Pharmaceutical applications of cyclodextrins. J Pharm Sci, 85:1017-1025
4. Stella VJ, Rajewski RA. (1997). Cyclodextrins: Their future in drug formulation and delivery. Pharm Res, 14:556-567
5. Akers MJ. (2002). Excipient-drug interactions in parenteral formulations. J Pharm Sci, 91:2283-2300
6. Floyd AG. (1999). Top ten considerations in the development of parenteral emulsions. Pharm Sci Tech, 4:134-143
7. Lawrence MJ, Rees GD. (2000). Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev, 45:89-121.
8. Nakano M. (2000). Places of emulsions in drug delivery. Adv Drug Deliv Rev, 45:1-4.
9. Weiner M, Bernstein IL. (1989). Adverse reactions to drug formulation agents. New York: Marcel Dekker.
10. Gad SC. (2002). Drug safety evaluation. New York: John Wiley and sons.
11. Nimmerfall F, Rosenthaler J. (1980). Dependence of area under the curve on proquazone particle size and in vitro dissolution rate. J Pharm Sci, 69:605-607
12. Shastri S, Mroszczak E, Prichard RK, Parekh P, Nguyen TH, Hennessey DR, et al. (1980). Relationship among particle size distribution, dissolution profile, plasma values and anthelmintic efficacy of oxfendazole. Am J Vet Res, 41: 2095-2101
13. Englund DE, Johansson ED. (1981). Oral versus vaginal absorption in oestradiol in postmenopausal women. Effects of different particle size. Ups J Med Sci, 86:297-307.
14. Watari N, Funaki T, Aizawa K, Kaneniwa N. (1983). Nonlinear assessment of nitrofurantoin bioavailability in rabbits. J Pharmacikinet Biopharm, 11:529-545
15. Hargrove JT, Maxson WS, Wentz AC. (1989). Absorption of oral progesterone is influenced by vehicle and particle size. Am J Obstet Gynecol, 161:948-951
16. Amidon GL, Lennernäs H, Shah VP, Crison JR. (1995). A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res, 12:413-420
17. Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP, et al. (2002). Biopharmaceutics classification system: The scientific basis for biowaiver extensions. Pharm Res, 19: 921-925
18. Lennernäs H, Abrahamsson B. (2005). The use of biopharmaceutic classification of drugs in drug discovery and development: Current status and future extension. J Pharm Pharmacol, 57:273-285
19. Kraml M, Dubuc J, Gaudry R. (1962). Gastrointestinal absorption of griseofulvin: II. Influence of particle size in man. Antibiot Chemother, 4:239-242
20. Mikota SK, Plumb DC. (2003). Griseofulvin; the Elephant Formulary. www.elephantcare.org [accessed June 6, 2003].
21. Liversidge GG, Cundy K. (1995). Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm, 125:91-97
22. Liversidge GG, Conzentino P. (1995). Drug particle reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int J Pharm, 125:309-313
23. Jia L, Wong J, Cerna C, Weitman S. (2002). Effect of nanonization on absorption of 301029: Ex vivo and in vivo pharmacokinetic correlations determined by liquid chromatography/mass spectrometry. Pharm Res, 19:1091-1096
24. Nernst W, Brunner E. (1904). Theorie der reaktionsgeschwindigkeit in heterogenen systemen. Z Physik Chemie, 47, 52-110.
25. Ziller KH, Rupprecht HH. (1990). Control of crystal growth in drug suspensions. Part II: Influence of polymers on dissolution and crystallization during temperature cycling. Pharm Ind, 52:1017-1022
26. Rabinow BE. (2004). Nanosuspensions in drug delivery. Nature Rev, 3:1-12.
27. Yasueda S, Higashiyama M, Shirasaki Y, Inada K, Ohtori A. (2004). An HPLC method to evaluate purity of a steroidal drug, Ioteprednol etabonate. J Pharm Biomed Anal, 36:309-316
28. Sigfridsson K, Andersson T, Nilsson L, Schönbacher V, Wang Y. (2007). Pharmaceutical and analytical characterization of (2R)- (3-amino-2-fluoropropyl)sulphinic acid, a GABAB receptor agonist. Eur J Pharm Biopharm, 65:104-110
29. Dressman JB, Reppas C. (2000). In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. Eur J Pharm Sci, 11:73-80.
30. Kesisoglou F, Panmai S, Wu Y. (2007). Nanosizing - oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev, 59:631-644
31. Mouton JW, van Peer A, de Beule K, van Vliet A, Donnelly JP, Soons PA. (2006). Pharmacokinetics of intraconazole and hydroxyitraconazole in healthy subjects after single and multiple doses of a novel formulation. Antimicrob Agents Chemother, 50:4096-4102
32. Xiong R, Lu W, Li J, Wang P, Xu R, Chen T. (2008). Preparation and characterization of intravenously injectable nimodipine nanosuspension. Int J Pharm, 350:338-343